Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use NOVOEIGHT safely and effectively. See full prescribing information for NOVOEIGHT.

NOVOEIGHT (antihemophilic factor, recombinant)
lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2013

RECENT MAJOR CHANGES
Indications and Usage (1) 12/2018
Dosage and Administration (2) 12/2018
Warnings and Precautions (5.2) 12/2018

INDICATIONS AND USAGE
Novoeight is an Antihemophilic Factor (Recombinant) indicated for use in adults and children with hemophilia A for:
• On-demand treatment and control of bleeding episodes
• Perioperative management
• Routine prophylaxis to reduce the frequency of bleeding episodes.
Novoeight is not indicated for the treatment of von Willebrand disease. (1)

DOSAGE AND ADMINISTRATION
For intravenous injection after reconstitution only (2)
• Each vial of Novoeight contains the labeled amount of recombinant Factor VIII in international units (IU). (2)
• The required dosage is determined using the following formula:
  Dosage Required (IU) = Body Weight (kg) × Desired Factor VIII Increase (IU/dL or % normal) × 0.5 (IU/kg per IU/dL)
• Frequency of Novoeight administration is determined by the type of bleeding episode and the recommendation of the treating physician. (2.1)

DOSAGE FORMS AND STRENGTHS
Novoeight is available as a lyophilized powder in single-use vials of 250, 500, 1000, 1500, 2000 and 3000 international units. (3)

CONTRAINDICATIONS
Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight or its components, including hamster proteins. (4)

WARNINGS AND PRECAUTIONS
• Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight and administer appropriate treatment. (5.1)
• Development of activity-neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration. (5.2, 5.3)

ADVERSE REACTIONS
The most frequently reported adverse reactions (≥ 1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia. (6)

USE IN SPECIFIC POPULATIONS
• Pediatric Use: Clearance (based on per kg body weight) is higher in children. Higher or more frequent dosing may be needed. (8.4)
• Obesity: The area under the curve (AUC) is higher and clearance lower in adult patients with body mass index (BMI) ≥ 30 kg/m² than in patients with BMI < 30 kg/m². Adjust dose as necessary. (8.6, 12.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Novoeight, Antihemophilic Factor (Recombinant), is a human antihemophilic factor (human blood coagulation factor VIII (FVIII)) indicated for use in adults and children with hemophilia A for:

- On-demand treatment and control of bleeding episodes
- Perioperative management
- Routine prophylaxis to reduce the frequency of bleeding episodes

Novoeight is not indicated for the treatment of von Willebrand disease.

2 DOSAGE AND ADMINISTRATION

For intravenous injection after reconstitution only.

2.1 Dose

- Dosage and duration of treatment depend on the severity of the factor VIII deficiency, on the location and extent of bleeding, and the patient’s clinical condition. Careful monitoring of replacement therapy is necessary in cases of major surgery or life-threatening bleeding episodes.

- Each vial of Novoeight contains the labeled amount of recombinant factor VIII in international units (IU). One IU of factor VIII activity corresponds to the quantity of factor VIII in one milliliter of normal human plasma. The calculation of the required dosage of factor VIII is based on the empirical finding that one IU of factor VIII per kg body weight raises the plasma factor VIII activity by two IU/dL. This relationship causes a factor of 0.5 to be present in the dose calculation formula shown below.

- The required dosage can be determined using the following formula:

\[
\text{Dosage (IU)} = \text{Body Weight (kg)} \times \text{Desired Factor VIII Increase (IU/dL or % normal)} \times 0.5
\]

The final dose calculated is expressed as IU

- Base the dose and frequency of Novoeight on the individual clinical response. Patients may vary in their pharmacokinetic and clinical responses [See Clinical pharmacology (12.3)].

On-demand Treatment and Control of Bleeding Episodes

A guide for dosing Novoeight for on-demand treatment and control of bleeding episodes is provided in Table 1. Dose to maintain a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 1.
Table 1: Dosing for On-demand Treatment and Control of Bleeding Episodes

<table>
<thead>
<tr>
<th>Type of Bleeding Episodes</th>
<th>Factor VIII Level Required (IU/dL or % of normal)</th>
<th>Frequency of Doses (hours)</th>
<th>Duration of Therapy (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor</td>
<td>20-40</td>
<td>12-24</td>
<td>At least 1 day until bleeding resolution is achieved</td>
</tr>
<tr>
<td></td>
<td>Early hemarthrosis, minor muscle or oral bleeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>30-60</td>
<td>12-24</td>
<td>Until pain and acute disability are resolved (approximately 3-4 days)</td>
</tr>
<tr>
<td></td>
<td>Muscle bleeding, bleeding into the oral cavity or mild head trauma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major</td>
<td>60-100</td>
<td>8-24</td>
<td>Until resolution of bleed (approximately 7-10 days)</td>
</tr>
<tr>
<td></td>
<td>Life or limb threatening hemorrhage, Gastrointestinal bleeding, intracranial, intra-abdominal or intrathoracic bleeding, fractures</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Perioperative Management

A guide for dosing Novoeight during surgery (perioperative management) is provided in Table 2. Consider maintaining a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 2.

Table 2: Dosing for Perioperative Management

<table>
<thead>
<tr>
<th>Type of Surgery</th>
<th>Factor VIII Level Required (IU/dL or % of normal)</th>
<th>Frequency of Doses (hours)</th>
<th>Duration of Therapy (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor</td>
<td>30-60</td>
<td>24</td>
<td>At least 1 day until healing is achieved</td>
</tr>
<tr>
<td>Including tooth extraction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major</td>
<td>80-100 (pre-and post-operative)</td>
<td>8-24</td>
<td>Until adequate wound healing, then continue therapy for at least 7 days to maintain a factor VIII activity of 30% to 60% (IU/dL)</td>
</tr>
<tr>
<td>Intracranial, intra-abdominal, intrathoracic, or joint replacement surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Routine Prophylaxis

A guide for dosing Novoeight for routine prophylaxis is included below in Table 3.

Table 3: Dosing for Routine Prophylaxis

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Factor VIII Dose Required (IU/kg)</th>
<th>Frequency of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults and adolescents (≥ 12 years)</td>
<td>20-50</td>
<td>3 times weekly</td>
</tr>
<tr>
<td></td>
<td>20-40</td>
<td>Every other day</td>
</tr>
<tr>
<td>Children (&lt;12 years)</td>
<td>25-60</td>
<td>3 times weekly</td>
</tr>
</tbody>
</table>
2.2 Preparation and Reconstitution

- Always wash hands and ensure that the area is clean before performing the procedures.
- Use aseptic technique during the reconstitution procedures.
- If the dose requires more than one vial of Novoeight per injection, reconstitute each vial according to the following instructions:

Overview of Novoeight Package

Reconstitution

1. Bring the Novoeight vial and the pre-filled diluent syringe to room temperature.

2. Remove the plastic cap from the Novoeight vial.

3. Wipe the rubber stopper on the vial with a sterile alcohol swab and allow it to dry prior to use.

4. Remove the protective paper from the vial adapter. **Do not remove the vial adapter from the protective cap.**

5. Place the vial on a flat and solid surface. While holding the protective cap, place the vial adapter over the Novoeight vial and press down firmly on the protective cap until the vial adapter spike penetrates the rubber stopper.

6. Carefully remove the protective cap from the vial adapter.
7. Grasp the plunger rod as shown in the diagram. Attach the plunger rod to the syringe by holding the plunger rod by the wide top end. Turn the plunger rod clockwise into the rubber plunger inside the pre-filled diluent syringe until resistance is felt.

8. Break off the syringe cap from the pre-filled diluent syringe by snapping the perforation of the cap.

9. Connect the pre-filled diluent syringe to the vial adapter by turning it clockwise until it is secured.

10. Push the plunger rod to slowly inject all the diluent into the vial.

11. Without removing the syringe, gently swirl the Novoeight vial until all of the powder is dissolved.

12. Use the Novoeight solution immediately. If not, store the solution in the vial with the vial adapter and the syringe attached. Use Novoeight within 4 hours after reconstitution when stored at <86°F (30°C) or within 2 hours when stored between 86°F (30°C) to 104°F (40°C).

2.3 Administration

For intravenous injection only.

- Inspect the reconstituted Novoeight solution visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is observed.
- Do not administer Novoeight in the same tubing or container with other medicinal products.

1. Invert the Novoeight vial and slowly draw the solution into the syringe.
2. Detach the syringe from the vial adapter by turning the syringe counterclockwise.
3. Attach the syringe to the luer end of an infusion needle set.
4. Inject the reconstituted Novoeight intravenously slowly over 2 to 5 minutes.
5. After injection, safely dispose of the syringe with the infusion set, the vial with the vial adapter, any unused Novoeight and other waste materials. Accidental needle stick with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate medical attention if injury occurs. Place needles in a sharps container after single-use.

Caution:
The pre-filled diluent syringe is made of glass with an internal tip diameter of 0.037 inches, and is compatible with a standard Luer-lock connector.

Some needleless connectors for intravenous catheters are incompatible with the glass diluent syringes (for example, certain connectors with an internal spike, such as Clave®/MicroClave®, InVision-Plus®, InVision-Plus CS®, Invision-Plus Junior®, Bionector®), and their use can damage the connector and affect administration. To administer Novoeight through incompatible needleless connectors, withdraw the reconstituted product into a standard 10 mL sterile Luer-lock plastic syringe.

3 DOSAGE FORMS AND STRENGTHS
Novoeight is available as a white lyophilized powder in single-use vials containing 250, 500, 1000, 1500, 2000 and 3000 international units per vial.

After reconstitution with 4 mL of 0.9% sodium chloride solution, each mL of reconstituted solution contains approximately 62.5, 125, 250, 375, 500 or 750 international units of Novoeight, respectively.

4 CONTRAINDICATIONS
Novoeight is contraindicated in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight or its components (including traces of hamster proteins).

5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, are possible with Novoeight. Novoeight contains trace amounts of hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Early signs of hypersensitivity reactions that can progress to anaphylaxis include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if allergic- or anaphylactic-type reactions occur.

5.2 Neutralizing Antibodies
Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of Novoeight. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs [see Adverse Reactions (6.1)]. Monitor all patients for the development of inhibitors by appropriate clinical observation and laboratory testing. If the expected plasma levels of factor VIII activity are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors.

5.3 Monitoring Laboratory Tests
• Monitor plasma factor VIII activity levels by the one-stage clotting assay or the chromogenic substrate assay to confirm that adequate factor VIII levels have been achieved and maintained, when clinically indicated. [See Dosage and Administration (2.1)]

• Perform assay to determine if factor VIII inhibitor is present if expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with the expected dose of Novoeight. Determine inhibitor levels in Bethesda Units.

6 ADVERSE REACTIONS

The most frequently reported adverse reactions observed in clinical trials (≥ 1%) were injection site reactions, and pyrexia.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.

During the clinical development of Novoeight, 301 male patients (242 previously treated patients (PTPs); exposed to a factor VIII-containing product for ≥150 days and 59 Previously Untreated Patients (PUPs)) with severe hemophilia A (factor VIII level ≤1%) received at least one dose of Novoeight as part of either routine prophylaxis, on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, Immune Tolerance Induction (ITI) or pharmacokinetic evaluation of Novoeight with more than 140,000 exposure days (corresponding to over 900 patient years). During prophylaxis treatment subjects received a median of 468 injections of Novoeight (range 1-1317).

Table 4: Summary of Adverse Reactions (ARs) with a Frequency ≥ 1% in 301 Subjects

<table>
<thead>
<tr>
<th>MedDRA System Organ class</th>
<th>Adverse Reactions</th>
<th>Frequency N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia</td>
<td>3 (1.0%)</td>
</tr>
<tr>
<td></td>
<td>Injection site reaction</td>
<td>3 (1.0%)</td>
</tr>
</tbody>
</table>

Immunogenicity

Subjects were monitored for neutralizing antibodies to factor VIII and binding antibodies to CHO and murine protein. No PTPs developed confirmed neutralizing antibodies to factor VIII. One twenty-two month old previously treated child had a positive neutralizing antibody to factor VIII of 1.3 [BU] in the Bethesda assay after 15 exposure days that was not confirmed when checked after 20 exposure days. In vivo recovery was normal for this child and no clinical adverse findings were observed. In the completed main phase of the clinical trial in PUPs, 24 of 56 (42.9%) patients developed inhibitors with a mean of 14.1 exposure days at the time of the first positive inhibitor test; 15 (26.8%) PUPs developed high titer (≥ 5 BU) inhibitors. High risk genetic mutations were identified in 91.7% of the overall inhibitors and 93.3% of the high titer inhibitors.

No patients developed de novo anti-murine antibodies. Nineteen subjects were positive for anti-Chinese hamster ovary (CHO) cell protein antibodies. Two of these subjects changed from anti-CHO negative to anti-CHO positive and 6 subjects changed from anti-CHO positive to anti-CHO negative. The remaining 11 subjects were either positive throughout the trials (n=6), negative at baseline and end-of trial but with transient positive samples (n=2), or positive at baseline and end-of trial but with negative samples in between (n=3). No clinical adverse findings were observed in any of these subjects.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to Novoeight with the incidence of antibodies to other products.

6.2 Postmarketing Experience

Adverse reactions reported during post marketing period were similar in nature to those observed during clinical trials.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy

Risk Summary

As hemophilia mainly affects males, there are no adequate and well-controlled studies using Novoeight in pregnant women to
determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Novoeight.

In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized
pregnancies is 2-4% and 15-20%, respectively. There is no reliable data on the incidences specific to the hemophilia A
population.

8.2 Lactation

Risk Summary

There is no information regarding the presence of Novoeight in human milk, the effect on the breastfed infant, and the effects
on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s
clinical need for Novoeight and any potential adverse effects on the breastfed infant from Novoeight or from the underlying
maternal condition.

8.4 Pediatric Use

Children have shorter half-life and lower recovery of factor VIII than adults. Because clearance (based on per kg body
weight) has been demonstrated to be higher in the pediatric population, higher or more frequent dosing based on body weight
may be needed. [See Clinical Pharmacology (12.3)]

Safety and efficacy studies have been performed in 146 pediatric patients <18 years of age. Ninety (including all 59 PUPs)
of these subjects (62%) were <6 years of age, 32 (22%) were 6 to <12 years of age, and 24 (16%) were adolescents (12 to
<18 years of age). Subjects during routine prophylaxis and treatment of bleeds received Novoeight at the dose levels
described in Tables 1 and 3. A total of 1290 bleeds in 127 subjects were treated with Novoeight. The majority of the bleeds
1162 (90%) were of mild/moderate severity. Of these 1290 bleeds, 1140 (88%) were rated excellent or good in their
response to treatment with Novoeight and in 17 (1%) the response to treatment was unknown. A total of 1100 (85%) of the
bleeds were resolved with one or two injections of Novoeight. Routine prophylactic treatment has been shown to reduce
joint bleeding. [See Clinical Studies (14)]

8.5 Geriatric Use

Clinical studies of Novoeight did not include sufficient numbers of patients aged 65 and over to determine whether they
respond differently from younger patients.

8.6 Obesity

In the extension trial, in six adult patients with body mass index (BMI) ≥ 30 kg/m², the AUC was higher and clearance lower
than in patients with BMI < 30 kg/m². There is insufficient data to recommend specific dose adjustments for patients with
BMI ≥ 30 kg/m². Adjust dose as necessary and per prescriber’s discretion for patients

11 DESCRIPTION

Novoeight is formulated as a sterile, non-pyrogenic, lyophilized powder for intravenous injection after reconstitution with the
diluent (0.9% sodium chloride). Novoeight is available in single-dose vials that contain nominally 250, 500, 1000, 1500,
2000 or 3000 international units (IU) per vial. When reconstituted with the appropriate volume of diluent, the product
contains the following components per mL: 18 mg sodium chloride, 1.5 mg L-histidine, 3 mg sucrose, 0.1 mg polysorbate 80,
0.055 mg L-methionine and 0.25 mg calcium chloride dihydrate. The product contains no preservative. Each vial of
Novoeight is labeled with the actual rFVIII activity expressed in IU determined by the one-stage clotting assay, using a
reference material calibrated against a World Health Organization (WHO) International Standard for FVIII Concentrates.
One IU, as defined by the WHO standard for human FVIII, is approximately equal to the level of FVIII activity in 1 mL of
fresh pooled human plasma. The specific activity of Novoeight is approximately 8340 IU per milligram of protein.

The active ingredient in Novoeight is a recombinant (r) analogue of human coagulation factor VIII (FVIII) with a molecular
mass of 166 kDa, calculated excluding post-translational modifications. The rFVIII molecule in Novoeight is a glycoprotein
containing a heavy chain and a light chain, with 21 of the 908 amino acids of the B-domain of endogenous FVIII connected
to the C-terminus of the heavy chain. Once activated, the resulting rFVIIIa has a comparable structure to the endogenous FVIIIa.

Novoeight is synthesized by a genetically engineered Chinese hamster ovary (CHO) cell line which secretes rFVIII into the cell culture medium. The rFVIII protein is purified using a series of chromatography steps, one of which is the use of an immunoaffinity column in which a monoclonal antibody, produced in CHO cells and directed against FVIII, is employed to selectively isolate the rFVIII from the medium. The production process includes two dedicated viral clearance steps - a detergent treatment step for inactivation and a 20-nm filtration step for removal of viruses. No additives of human or animal origin are used in the cell culture, purification and formulation of Novoeight.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Novoeight temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis.

12.2 Pharmacodynamics

The activated partial thromboplastin time (aPTT) is prolonged in patients with hemophilia A. Determination of aPTT is a conventional \textit{in vitro} assay for the biological activity of FVIII. Treatment with Novoeight normalizes the aPTT over the effective dosing period.

12.3 Pharmacokinetics

All pharmacokinetic studies with Novoeight were conducted in previously treated patients with severe hemophilia A (factor VIII $\leq$ 1%). Analysis of plasma samples was conducted using both the one-stage clotting assay and the chromogenic assay.

In a multi-center, multi-national, open-label, single dose pharmacokinetic study, 23 patients with severe hemophilia A received 50 international units/kg of Novoeight intravenously. Two patients were below the age of 18 years (13 and 17 years). The pharmacokinetic parameters for 20 patients who completed the study are summarized in Table 5.

Table 5: Pharmacokinetics of Novoeight in 20 adult and adolescent patients with hemophilia A$^a$

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Clotting Assay</th>
<th>Chromogenic Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental Recovery (IU/mL)/(IU/kg)</td>
<td>0.020 (0.002)</td>
<td>0.028 (0.006)</td>
</tr>
<tr>
<td>$\text{AUC}$ (IU*h/mL)</td>
<td>14.2 (3.8)</td>
<td>18.7 (5.1)</td>
</tr>
<tr>
<td>$\text{CL}$ (mL/h/kg)</td>
<td>3.74 (0.95)</td>
<td>2.87 (0.80)</td>
</tr>
<tr>
<td>$t_{1/2}$ (h)</td>
<td>10.8 (4.9)</td>
<td>12.0 (9.3)</td>
</tr>
<tr>
<td>$V_{ss}$ (mL/kg)</td>
<td>53.4 (10.9)</td>
<td>44.3 (28.2)</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (IU/mL)</td>
<td>1.07 (0.16)</td>
<td>1.54 (0.29)</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>15.4 (6.4)</td>
<td>16.4 (10.1)</td>
</tr>
</tbody>
</table>

$^a$Dose: 50 IU/kg turoctocog alfa (single i.v. dose)

In a single dose PK assessment in adult patients with BMI $\geq$ 30 kg/m$^2$ in the extension trial [See Clinical Studies (14)], the AUC was 59% higher and clearance was 33% lower in 6 subjects with BMI $\geq$ 30 kg/m$^2$ compared to subjects with normal BMI, see Table 6.
Table 6: Pharmacokinetics of Novoeight in 6 adult patients with BMI ≥ 30 kg/m²

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Clotting Assay</th>
<th>Chromogenic Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>33.35 (2.367)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range 30.5 – 37.2</td>
<td></td>
</tr>
<tr>
<td>Incremental Recovery</td>
<td>0.024 (0.01)</td>
<td>0.035 (0.01)</td>
</tr>
<tr>
<td>(IU/mL)/(IU/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC (IU*h/mL)</td>
<td>22.64 (5.74)</td>
<td>31.02 (9.78)</td>
</tr>
<tr>
<td>CL (mL/h/kg)</td>
<td>2.49 (0.77)</td>
<td>1.94 (0.95)</td>
</tr>
<tr>
<td>t½ (h)</td>
<td>12.80 (2.99)</td>
<td>12.40 (3.16)</td>
</tr>
<tr>
<td>Vss (mL/kg)</td>
<td>39.67 (10.03)</td>
<td>29.79 (7.87)</td>
</tr>
<tr>
<td>Cmax (IU/mL)</td>
<td>1.49 (0.36)</td>
<td>2.03 (0.51)</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>16.84 (4.78)</td>
<td>16.58 (4.26)</td>
</tr>
</tbody>
</table>

Dose: 50 IU/kg turoctocog alfa (single i.v. dose)

In a separate pharmacokinetic study, 28 pediatric patients with severe hemophilia A (14 patients were below 6 years of age and 14 patients were between 6 to <12 years of age) received a single dose of 50 international units/kg Novoeight. The pharmacokinetic parameters of Novoeight are summarized in Table 7 for both age groups.

Table 7: Pharmacokinetics of Novoeight in 28 pediatric patients with hemophilia A

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Clotting Assay</th>
<th>Chromogenic Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 to &lt;6 years</td>
<td>6 to &lt;12 years</td>
</tr>
<tr>
<td>Incremental Recovery</td>
<td>0.018 (0.007)</td>
<td>0.020 (0.004)</td>
</tr>
<tr>
<td>(IU/mL)/(IU/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC (IU*h/mL)</td>
<td>9.9 (4.1)</td>
<td>11.1 (3.7)</td>
</tr>
<tr>
<td>CL (mL/h/kg)</td>
<td>6.26 (3.73)</td>
<td>5.02 (1.67)</td>
</tr>
<tr>
<td>t½ (h)</td>
<td>7.7 (1.8)</td>
<td>8.0 (1.9)</td>
</tr>
<tr>
<td>Vss (mL/kg)</td>
<td>57.3 (26.8)</td>
<td>46.8 (10.6)</td>
</tr>
<tr>
<td>Cmax (IU/mL)</td>
<td>1.00 (0.58)</td>
<td>1.07 (0.35)</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>9.7 (2.5)</td>
<td>9.9 (2.6)</td>
</tr>
</tbody>
</table>

The pharmacokinetic parameters were comparable between younger (0 to < 6 years) and older (6 to < 12 years) children. The mean clearance of Novoeight in younger and older children was 67% and 34% higher (based on per kg body weight) than in adults (3.74 mL/h/kg) when using the clotting assay, and 60% and 29% higher than in adults (2.87 mL/h/kg) when using the chromogenic assay. The mean half-life of Novoeight in younger and older children was 29% and 26% shorter than in adults (10.8 hours) when using the clotting assay, and 16% and 21% shorter than in adults (12 hours) when using the chromogenic assay.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate the carcinogenic potential of Novoeight, or studies to determine the effects of Novoeight on genotoxicity or fertility have not been performed. An assessment of the carcinogenic potential of Novoeight was completed, and no carcinogenic risk from product use has been identified.

14 CLINICAL STUDIES

Four multi-center, open-label, non-controlled trials have been conducted to evaluate the safety and efficacy of Novoeight in the on-demand treatment and control of breakthrough bleeds, routine prophylaxis and perioperative management in patients with hemophilia A. Three of these trials were performed in PTPs (two trials and one extension trial) and the fourth in PUPs. The analysis included 297 exposed subjects: 175 previously treated adolescents or adult subjects from the age of 12 years (≥150 exposure days), 63 previously treated pediatric subjects below the age of 12 years (≥50 exposure days) and 59 PUPs below 6 years of age. Immunocompetent patients with severe hemophilia A (factor VIII activity ≤1%) and no history of FVIII inhibitors were eligible for the trials. Subjects during routine prophylaxis and treatment of bleeds received Novoeight...
at the dose levels described in Tables 1 and 3. Breakthrough bleeds were treated at the investigator’s discretion aiming for a FVIII activity level above 0.5 IU/mL. Treatment during surgery was at the investigator’s discretion aiming for a FVIII trough activity level above 0.5 IU/mL.

### On-demand Treatment and Control of Bleeding Episodes

A total of 3153 bleeds in 260 subjects were treated with Novoeight. The majority of the bleeds (90%) were of mild/moderate severity, 54% of the bleeds were spontaneous and 67% of the bleeds were localized in joints.

An overall assessment of efficacy was performed by the subject (for home treatment) or study site investigator (for treatment under medical supervision) using a four-point scale of excellent, good, moderate, or none. If the hemostatic response was rated as “excellent” or “good”, the treatment of the bleed was considered a success. If the hemostatic response was rated as “moderate or none” the treatment was considered a failure. Of these 3,153 bleeds, 2,809 (89%) were rated excellent or good in their response to treatment with Novoeight, 274 (9%) were rated as moderate, 25 (0.8%) were rated as having no response and for 45 (1%) the response to treatment was unknown. A total of 2,794 (89%) of the bleeds were resolved with one or two injections of Novoeight.

Of the 238 PTPs, 206 patients experienced 2,793 bleeds of which 2,492 (89%) were rated excellent or good in their response to treatment with Novoeight, 244 (9%) were moderate, 23 (0.8%) were rated as having no response, and for 34 (1%) the response to treatment was unknown. Of the 2,793 reported bleeds observed in 206 of the patients, 2,504 (90%) of the bleeds were resolved with 1–2 injections of Novoeight. The majority of the bleeds were of mild/moderate severity.

Of the 59 PUPs, 54 patients experienced 360 bleeds of which 317 (88%) were rated excellent or good in their response to treatment with Novoeight, 30 (8%) were moderate, 2 (0.6%) were rated as having no response, and for 11 (3%) the response to treatment was unknown. Of the 360 reported bleeds observed in 54 of the patients, 290 (81%) of the bleeds were resolved with 1–2 injections of Novoeight. The majority of the bleeds were of mild/moderate severity and the most frequent bleeds were subcutaneous.

### Routine Prophylaxis

In the two trials, one trial including 150 adult/adolescent subjects (6 months duration) and the other trial including 63 pediatric subjects (4 months duration) received Novoeight for routine prophylaxis (Table 8). These previously treated patients received prophylaxis treatment every other day or three times weekly at the dose levels described in Table 3.

#### Table 8: Annualized Bleeding Rate (ABR) for previously treated patients from the two trials

<table>
<thead>
<tr>
<th></th>
<th>Small children 0 - &lt;6 years</th>
<th>Older children 6 - &lt;12 years</th>
<th>Adolescents 12 - &lt;18 years</th>
<th>Adults ≥18 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>31</td>
<td>32</td>
<td>24</td>
<td>126</td>
<td>213</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>2.97 (6.30)</td>
<td>3.65 (8.93)</td>
<td>3.98 (6.21)</td>
<td>3.70 (9.02)</td>
<td>3.67 (8.70)</td>
</tr>
<tr>
<td>Mean (95%CI)</td>
<td>4.77 (3.07; 7.41)</td>
<td>5.93 (3.81; 9.22)</td>
<td>5.48 (3.29; 9.14)</td>
<td>6.69 (5.36; 8.36)</td>
<td>6.24 (5.25; 7.41)</td>
</tr>
</tbody>
</table>

**a:** The ABRs were estimated using a Poisson model allowing for overdispersion.

**b:** Patients dosed every other day or three times weekly

**Abbreviations:** N: number of patients; IQR: interquartile range defined as the difference between the 75th percentile and the 25th percentile; CI: confidence interval.

One hundred and eighty-eight (188) subjects from the two trials above continued into the extension trial (up to 6 years duration) (Table 9). Additionally, 18 subjects (7 subjects from an on-demand sub-trial and 11 subjects from a pharmacokinetic trial) were included in the extension trial. These previously treated patients received prophylaxis treatment every other day or three times weekly at the dose levels described in Table 3.

#### Table 9: Annualized Bleeding Rate (ABR) for previously treated patients from the extension trial

<table>
<thead>
<tr>
<th></th>
<th>Small children 0 - &lt;6 years</th>
<th>Older children 6 - &lt;12 years</th>
<th>Adolescents 12 - &lt;18 years</th>
<th>Adults ≥18 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>27</td>
<td>28</td>
<td>23</td>
<td>128</td>
<td>206</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>1.08 (2.83)</td>
<td>1.57 (3.82)</td>
<td>1.57 (2.34)</td>
<td>1.38 (2.96)</td>
<td>1.39 (2.94)</td>
</tr>
<tr>
<td>Mean (95%CI)</td>
<td>1.87 (1.14; 3.09)</td>
<td>2.90 (2.01; 4.17)</td>
<td>1.93 (1.33; 2.82)</td>
<td>2.61 (2.08; 3.28)</td>
<td>2.45 (2.07; 2.90)</td>
</tr>
</tbody>
</table>

**a:** The ABRs were estimated using a Poisson model allowing for overdispersion.

**b:** Patients dosed every other day or three times weekly

**Abbreviations:** N: number of patients; IQR: interquartile range defined as the difference between the 75th percentile and the 25th percentile; CI: confidence interval.
In the trial with previously untreated patients, 56 subject below 6 years of age received Novoeight for routine prophylaxis. The median annualized bleeding rate in the previously untreated patients was 2.9 (IQR 5.4) and the mean (95%CI) was 4.4 (3.3; 5.8).

Perioperative Management

A total of 30 surgeries were performed in 25 previously treated subjects between 8 and 58 years of age, of which 26 were major surgeries (20 orthopaedic, 5 non-orthopaedic and a circumcision), and 4 were minor (2 dental, 1 circumcision and 1 insertion of port-a-cath).

The investigator’s ratings of intra- and post-operative quality of hemostasis for these subjects were “excellent” or “good” for all cases.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

- Novoeight is supplied in packages comprised of a single-use vial containing nominally 250, 500, 1000, 1500, 2000, or 3000 international units (IU) of FVIII potency, a MixPro® pre-filled diluent syringe containing 0.9% sodium chloride solution, and sterile vial adapter with 25 micrometer filter, which serves as a needleless reconstitution device.

- The actual amount of FVIII potency in IU is stated on each carton and vial.

<table>
<thead>
<tr>
<th>Presentation (Nominal Product Strength)</th>
<th>Carton NDC Number</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 International Units</td>
<td>NDC 0169 7825 01</td>
<td>Novoeight in single-use vial [NDC 0169-7829-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
<tr>
<td>500 International Units</td>
<td>NDC 0169 7850 01</td>
<td>Novoeight in single-use vial [NDC 0169-7851-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
<tr>
<td>1000 International Units</td>
<td>NDC 0169 7810 01</td>
<td>Novoeight in single-use vial [NDC 0169-7811-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
<tr>
<td>1500 International Units</td>
<td>NDC 0169 7815 01</td>
<td>Novoeight in single-use vial [NDC 0169-7855-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
<tr>
<td>2000 International Units</td>
<td>NDC 0169 7820 01</td>
<td>Novoeight in single-use vial [NDC 0169-7821-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
<tr>
<td>3000 International Units</td>
<td>NDC 0169 7830 01</td>
<td>Novoeight in single-use vial [NDC 0169-7831-11]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-filled sodium chloride diluent in syringe, 4 mL [NDC 0169-7008-98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vial adapter</td>
</tr>
</tbody>
</table>

- The Novoeight vials are made of glass, closed with a chlorobutyl rubber stopper not made with natural rubber latex, and sealed with an aluminum cap.
- The pre-filled diluent syringes are made of glass, with a siliconised bromobutyl rubber plunger not made with natural rubber latex.
- The closed vials and pre-filled diluent syringes are equipped with a tamper-evident snap-off cap which is made of polypropylene.
Storage and Handling

- Store Novoeight in the original package in order to protect from light.
- Store Novoeight under refrigeration at a temperature of 36°F to 46°F (2°C to 8°C) for up to 30 months from the date of manufacture until the expiration date stated on the carton. During the 30-month shelf life, Novoeight may be kept at room temperature:
  - up to 86°F (≤30°C) for no longer than 12 months
  - up to 104°F (≤40°C) for no longer than 3 months
- Clearly record the date when the product was removed from the refrigerator in the space provided on the outer carton. Do not return the product to the refrigerator. Do not freeze Novoeight.
- Use Novoeight within 4 hours after reconstitution when stored at <86°F (30°C) or within 2 hours when stored between 86°F (30°C) to 104°F (40°C). Store the reconstituted product in the vial.
- Discard any unused reconstituted product.

17 PATIENT COUNSELING INFORMATION

- Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
- Allergic-type hypersensitivity reactions or anaphylaxis are possible with use of Novoeight. Inform patients of the early signs of hypersensitivity reactions including rash, hives, itching, facial swelling, tightness of the chest and wheezing. Advise patients to discontinue use of Novoeight immediately and contact their physician, and go to the emergency department if these symptoms occur.
- Advise patients to contact their physician or treatment facility for further treatment and/or assessment if they experience a lack of a clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor.
- Advise patients to consult with their healthcare provider prior to traveling. While traveling, patients should be advised to bring an adequate supply of Novoeight based on their current treatment regimen.

Version: 7

License Number: 1261

Novoeight® and MixPro® are registered trademarks of Novo Nordisk Health Care AG.

Clave® and MicroClave® are registered trademarks of ICU Medical Inc.
InVision-Plus®, InVision-Plus CS®, Invision-Plus® Junior® are registered trademarks of RyMed Technologies, Inc.
Bionector® is a registered trademark of Vygon.
© 2018 Novo Nordisk

For information contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536, USA
1-844-30-EIGHT

Manufactured by:
Novo Nordisk A/S
Novo Allé, DK-2880 Bagsvaerd